VBI Vaccines (NASDAQ: VBIV) and Mirati Therapeutics (NASDAQ:MRTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Volatility & Risk

VBI Vaccines has a beta of 2.67, suggesting that its share price is 167% more volatile than the S&P 500. Comparatively, Mirati Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500.

Institutional and Insider Ownership

31.5% of VBI Vaccines shares are owned by institutional investors. Comparatively, 60.1% of Mirati Therapeutics shares are owned by institutional investors. 54.5% of VBI Vaccines shares are owned by insiders. Comparatively, 5.1% of Mirati Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for VBI Vaccines and Mirati Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VBI Vaccines 0 0 1 0 3.00
Mirati Therapeutics 0 3 7 0 2.70

Mirati Therapeutics has a consensus target price of $13.88, suggesting a potential downside of 11.90%. Given Mirati Therapeutics’ higher probable upside, analysts clearly believe Mirati Therapeutics is more favorable than VBI Vaccines.

Profitability

This table compares VBI Vaccines and Mirati Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
VBI Vaccines N/A N/A N/A
Mirati Therapeutics N/A -101.85% -86.50%

Valuation and Earnings

This table compares VBI Vaccines and Mirati Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
VBI Vaccines $888,999.00 159.74 -$32.88 million N/A N/A
Mirati Therapeutics N/A N/A -$73.47 million ($3.43) -4.59

VBI Vaccines has higher revenue and earnings than Mirati Therapeutics.

Summary

VBI Vaccines beats Mirati Therapeutics on 7 of the 10 factors compared between the two stocks.

VBI Vaccines Company Profile

VBI Vaccines Inc., formerly SciVac Therapeutics Inc., is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens. It is engaged in developing an experimental CMV vaccine using its eVLP vaccine platform. The vaccine is based on the CMV glycoprotein B antigen and is adjuvanted with aluminum phosphate. The eVLP vaccine technology allows for the expression of envelope glyco-proteins within a lipid-bilayer membrane of a VLP. It is developing a therapeutic vaccine candidate for glioblastoma multiforme (GBM). It is developing a vaccine to prevent respiratory syncytial virus (RSV) infection. It also offers Sci-B-Vac, which is a third-generation hepatitis B vaccine.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with MarketBeat.com's FREE daily email newsletter.